$LLY, Price correction?Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
Positive:
Yields high return on invested capital
Has raised its dividend for 8 consecutive years
13 analysts have revised their earnings upwards for the upcoming period
Prominent player in the Pharmaceuticals industry
Cash flows can sufficiently cover interest payments
High return over the last year
An analyst from Morgan Stanley maintained Eli Lilly (NYSE: LLY) at 'overweight' with a price target of $640.00 from a prior price target of $617.00.
Negative:
Trading at a high earnings multiple
Corporate insiders Sold shares worth $21.3B in the past 3 months
Hedge funds Sold 789.5K shares in the past quarter
Very strong bullish trend, it is expecting a price correction after this stock should follow